Ozempic GLP-1 Class Action Lawsuit Guide 2025: Compensation, Settlements & Eligibility

Patients are filing lawsuits against Novo Nordisk, the maker of Ozempic (semaglutide), alleging the drug causes severe and unexpected side effects. The two primary injuries at the center of the Ozempic lawsuit are gastroparesis (stomach paralysis) and vision loss linked to optic nerve damage. Claims argue that the manufacturer failed to provide adequate warnings about these risks, leaving patients vulnerable to life-altering harm.

Start your free claim review

Ozempic Class Action Lawsuit Guide: Eligibility, Injuries, Settlements & Filing Steps

This guide explains who qualifies for an Ozempic injury lawsuit, the key medical complications at issue, evidence that supports claims, potential settlement factors, recent lawsuit updates, and how the legal process works.

Who Qualifies for an Ozempic Lawsuit?

• Used Ozempic (semaglutide) for diabetes or weight loss
• Later diagnosed with gastroparesis (stomach paralysis) or vision loss tied to optic nerve damage
• Experienced long-term complications, hospitalizations, or permanent disability

See if you qualify — free & confidential.

Ozempic Injuries: Gastroparesis & Vision Loss

1. Gastroparesis (Stomach Paralysis): Patients allege that Ozempic causes severe gastric slowing, leading to chronic nausea, vomiting, abdominal pain, malnutrition, and hospitalizations. Some cases require feeding tubes or surgical intervention.

2. Vision Loss / Optic Nerve Damage: Lawsuits also claim Ozempic use is linked to optic nerve ischemia and permanent vision loss. Patients report sudden or progressive blindness, blurred vision, or other sight-threatening complications.

What Evidence Supports an Ozempic Case

• Prescription history documenting Ozempic use (dose, duration)
• Medical records confirming gastroparesis or optic nerve damage diagnosis
• Hospitalization reports or surgical interventions tied to GI complications
• Ophthalmology records for vision loss claims
• Impact documentation: lost wages, daily limitations, long-term disability

Ozempic Lawsuit Settlements & Key Factors

Since litigation is ongoing, no global Ozempic settlement has been reached. Factors that may influence case value include:

• Type of injury: gastroparesis vs. permanent vision loss
• Severity: hospitalizations, surgical interventions, blindness
• Liability: strength of failure-to-warn evidence
• Venue & jury trends: some courts award higher damages in pharmaceutical cases

* Educational only; settlement outcomes vary by case facts and jurisdiction.

Ozempic Lawsuit Updates – August 2025

• 2025: Federal lawsuits continue to grow as patients allege Ozempic causes gastroparesis and vision loss. Judges are reviewing case coordination requests.
• 2024: Medical studies linked GLP-1 drugs like Ozempic to severe delayed gastric emptying and reports of optic nerve damage.
• 2023: Early filings alleged permanent injuries including stomach paralysis and vision loss, with claims focused on failure to warn patients of these risks.

We update this section monthly with MDL activity, notable filings, and verdicts.

How the Ozempic Lawsuit Process Works

1. Free evaluation: Provide prescription history and medical records.
2. Investigation: Attorneys review evidence and consult gastroenterology/ophthalmology experts.
3. Filing: Claims may be filed individually or coordinated in federal MDL proceedings.
4. Discovery & negotiation: Exchange medical records, expert opinions, explore settlement or mediation.
5. Resolution: Settlement, mediation, or trial depending on case facts.

Start your free claim review — no upfront fees.

Ozempic Lawsuit FAQs

Sources

• NIH: GLP-1 Agonists & Delayed Gastric Emptying
• AAO: Reports of Vision Loss in GLP-1 Drug Users
• NEJM: Semaglutide Studies

Related Lawsuits

• Enfamil & Similac NEC Baby Formula Lawsuit
• Video Game Addiction Lawsuit
• Hernia Mesh Lawsuit
• Zantac Cancer Lawsuit
• CPAP Device Recall Lawsuit
• Paragard IUD Lawsuit
• Roundup Cancer Lawsuit

Get a Free Case Review

Answer a few questions to see if you qualify. Your information is confidential. No upfront fees.